These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17527008)

  • 1. [Recent topics in the treatment of osteoporosis in Japan].
    Miki T
    Nihon Ronen Igakkai Zasshi; 2007 Mar; 44(2):165-7. PubMed ID: 17527008
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-estrogen treatments for osteoporosis: an evidence-based review.
    Bushardt RL; Turner JL; Ragucci KR; Askins DG
    JAAPA; 2006 Dec; 19(12):25-30. PubMed ID: 17243258
    [No Abstract]   [Full Text] [Related]  

  • 3. [Application of anti-resorptive drugs for the treatment of osteoporosis].
    Takada J
    Nihon Rinsho; 2006 Feb; 64(2):385-91. PubMed ID: 16454196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis.
    Kim Y; Tian Y; Yang J; Huser V; Jin P; Lambert CG; Park H; You SC; Park RW; Rijnbeek PR; Van Zandt M; Reich C; Vashisht R; Wu Y; Duke J; Hripcsak G; Madigan D; Shah NH; Ryan PB; Schuemie MJ; Suchard MA
    Sci Rep; 2020 Jul; 10(1):11115. PubMed ID: 32632237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summaries for patients. Drug therapy for osteoporosis.
    Ann Intern Med; 2008 May; 148(9):I28. PubMed ID: 18458273
    [No Abstract]   [Full Text] [Related]  

  • 6. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract]   [Full Text] [Related]  

  • 7. Alveolar bone dynamics in osteoporotic rats treated with raloxifene or alendronate: confocal microscopy analysis.
    Ramalho-Ferreira G; Faverani LP; Grossi-Oliveira GA; Okamoto T; Okamoto R
    J Biomed Opt; 2015 Mar; 20(3):038003. PubMed ID: 25813805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review.
    Fujiwara S; Miyauchi A; Hamaya E; Nicholls RJ; Weston A; Baidya S; Pinto L; Barron R; Takada J
    Arch Osteoporos; 2018 Mar; 13(1):34. PubMed ID: 29564555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
    Siris ES; Modi A; Tang J; Gandhi S; Sen S
    Curr Med Res Opin; 2014 Jan; 30(1):123-30. PubMed ID: 24102262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controversies in osteoporosis management: antiresorptive therapy for preventing bone loss: when to use one or two antiresorptive agents?
    Gallagher JC; Tella SH
    Clin Obstet Gynecol; 2013 Dec; 56(4):749-56. PubMed ID: 24036481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy.
    Apkon S; Coll J
    Am J Phys Med Rehabil; 2008 Feb; 87(2):139-43. PubMed ID: 17912140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the prescribing pattern of bisphosphonate and raloxifene in Korean women with osteoporosis: from a national health insurance claims database.
    Kim J; Shin JY; Lee J; Song HJ; Choi NK; Park BJ
    PLoS One; 2015; 10(6):e0127970. PubMed ID: 26030300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bone quality].
    Ito M
    Nihon Rinsho; 2009 May; 67(5):921-5. PubMed ID: 19432110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
    Liu Q; Chen D; Ye Z; Jin Z; Ma T; Huang X
    Medicine (Baltimore); 2020 Oct; 99(40):e22542. PubMed ID: 33019463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

  • 16. Secondary prevention of osteoporosis in Australia: analysis of government-dispensed prescription data.
    Hollingworth SA; Gunanti I; Nissen LM; Duncan EL
    Drugs Aging; 2010 Mar; 27(3):255-64. PubMed ID: 20210370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fracture risk and treatment in chronic kidney disease.
    Connelly K; Collister D; Tangri N
    Curr Opin Nephrol Hypertens; 2018 May; 27(3):221-225. PubMed ID: 29547405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
    Nakatoh S
    J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of bone quality. Effects of bisphosphonates, raloxifene, alfacalcidol, and menatetrenone on bone quality: collagen cross-links, mineralization, and microdamage].
    Saito M
    Clin Calcium; 2008 Mar; 18(3):364-72. PubMed ID: 18310825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of SERMs on bone health. SERM and metabolic markers of bone].
    Takami M; Shimada H
    Clin Calcium; 2010 Mar; 20(3):365-71. PubMed ID: 20190366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.